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Vaccine adjuvants are traditionally used to augment and modulate the immunogenicity
of vaccines, although in many cases it is unclear which specific molecules contribute to
their stimulatory activity. We previously reported that both subcutaneous and intranasal
administration of hydroxypropyl-β-cyclodextrin (HP-β-CD), a pharmaceutical excipient
widely used to improve solubility, can act as an effective adjuvant for an influenza
vaccine. However, the mechanisms by which mucosal immune pathway is critical
for the intranasal adjuvant activity of HP-β-CD have not been fully delineated. Here,
we show that intranasally administered HP-β-CD elicits a temporary release of IL-33
from alveolar epithelial type 2 cells in the lung; notably, IL-33 expression in these
cells is not stimulated following the use of other vaccine adjuvants. The experiments
using gene deficient mice suggested that IL-33/ST2 signaling is solely responsible
for the adjuvant effect of HP-β-CD when it is administered intranasally. In contrast,
the subcutaneous injection of HP-β-CD and the intranasal administration of alum,
as a damage-associated molecular patterns (DAMPs)-inducing adjuvant, or cholera
toxin, as a mucosal adjuvant, enhanced humoral immunity in an IL-33-independent
manner, suggesting that the IL-33/ST2 pathway is unique to the adjuvanticity of
intranasally administered HP-β-CD. Furthermore, the release of IL-33 was involved in the
protective immunity against influenza virus infection which is induced by the intranasal
administration of HP-β-CD-adjuvanted influenza split vaccine. In conclusion, our results
suggest that an understanding of administration route- and tissue-specific immune
responses is crucial for the design of unique vaccine adjuvants.
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INTRODUCTION
Vaccines are one of the most effective preventive measures
for diseases. However, as the threat of infectious diseases
diminishes, vaccine safety is increasing in importance,
particularly in developed countries. Subunit vaccines that
use more purified antigens have a high safety profile but
are often poorly immunogenic. To improve the immune
response to subunit vaccines, vaccine adjuvants have been
actively developed in recent years (1–3). Unfortunately,
many of the candidate adjuvants proved too reactogenic
and were poorly tolerated, so they did not advance further
into clinical development. At present, there are just a few
US Food and Drug Administration (US-FDA)-approved
adjuvants. Furthermore, despite widespread research on vaccine
adjuvants, there is little known regarding the pathways affected
by many potential adjuvants. Pattern-associated molecular
patterns (PAMPs), acting via pathogen-recognition receptors
(PRRs), such as Toll-like receptors (TLRs), cytosolic nucleotide
oligomerization domain-like receptors (NODs), retinoic acid-
inducible gene-based-I (RIG-I)-like receptors (RLRs), and
C-type lectin-like receptors (CLRs), are one of category of
immunopotentiating molecules, and they have been widely
employed in preclinical and clinical studies (4). In contrast, the
precise roles of innate recognition for other adjuvants, such as
alum (despite being the most widely adjuvant), emulsions, and
particulates are less characterized. To rationally design vaccines
against various diseases and obtain information on adjuvant
safety, we need to understand the mechanisms involved in
adjuvant-enhanced immunity.
In recent years, mucosal immunity has attracted a lot of
attention, and there has been a corresponding focus on the
mucosal route of vaccination (5–7). However, attempts to
develop mucosal vaccines have not yet been successful, in
part because they require adjuvants suitable for characteristic
mucosal environments to obtain adequate vaccine effects (8, 9).
Recently, we reported that hydroxypropyl-β-cyclodextrin (HP-
β-CD) has potent adjuvant activities in mice and cynomolgus
monkeys (10–12). In those studies, we found that the intranasal
administration of HP-β-CD can enhance the secretion of antigen-
specific IgG and IgA into the serum and the airway fluid and the
administration of an intranasal flu vaccine adjuvanted with HP-
β-CD protected mice against a lethal challenge with influenza
virus. Additionally, it was suggested that enhanced humoral
immunity by intranasally administered HP-β-CD was mediated
by MyD88, which is the downstream signaling molecule for
TLRs, but also for IL-1 family cytokines including IL-1 and IL-
33. Although HP-β-CD is thought to show the adjuvanticity by
stimulating the release of damage-associated molecular patterns
(DAMPs) because temporary release of double-strand DNA was
detected after intranasal and subcutaneous injection, the detailed
mechanism of adjuvanticity for intranasally administered HP-β-
CD remains poorly understood.
Here, we found that IL-33, but not IL-1 is released from
alveolar epithelial cells following the intranasal administration
of HP-β-CD and that IL-33-mediated signaling was essential
for its adjuvanticity. Moreover, we found completely different




Ovalbumin protein (OVA; Kantokagaku, Tokyo, Japan) was
used as a model antigen. HP-β-CD (ISP Technologies, Assonet,
MA, USA), Alhydrogel (alum; Invivogen, San Diego, CA, USA),
cholera toxin (CT), cholera toxin B subunit (CTB) (Wako,
Osaka, Japan) and recombinant mouse IL-33 (R&D systems,
Minneapolis, MN, USA) were used as adjuvants. Influenza split
vaccine (SV) was manufactured with egg-based technology.
SV contains influenza virus hemagglutinin (HA) surface Ag
fromNewCaledonia/20/1999 (H1N1) (The Research Foundation
for Microbial Diseases of Osaka University) as previously
described (11).
Mice
C57BL/6J mice were obtained from CLEA Japan, Inc. (Tokyo,
Japan). Tlr4 −/−, Tlr7−/−, Tlr9 −/−, Il33−/−, Il1r1−/−, St2−/−,
and Il13−/− mice were kindly provided by Dr. Akira (13–
15), Dr. Nakanishi (16), Dr. Ziegler (17), and Dr. McKenzie
(18). Tnf/Tbk1-knockout mice were prepared as described (19).
Il1r1−/− mice were purchased from the Jackson Laboratory
(Maine, U.S.A.). These deficient mice were bred on a C57BL/6
background and housed under specific pathogen-free conditions
in the animal facility of the National Institute of Biomedical
Innovation, Health and Nutrition (NIBIOHN). Mice were
age- and sex-matched and were 6–9 weeks old when used
in experiments. The experiments with Il13−/− mice were
performed in National Research Institute for Child Health
and Development (NCCHD). All animal experiments were
performed according to the guidelines for the care and use of
laboratory animals established by NIBIOHN and NCCHD.
Immunization of Mice and Preparation of
Lung Washes and Serum
Antigens and adjuvants were each dissolved in PBS. In
the vaccination model, mice were immunized intranasally or
subcutaneously twice at 2 week intervals, with a solution
containing 10 µg of OVA with or without adjuvant. Nasal
and subcutaneous administration volumes were 15 µl into
each nostril and 200 µl into the dorsal flank, respectively. All
immunizations were performed under anesthetic (ketamine and
xylazine). Blood and bronchoalveolar lavage fluid (BALF) were
taken on day 28. Blood was collected using heparinized capillary
tubes and centrifuged at 2,500× g for 5min. The plasmawas then
collected and stored frozen at −40◦C until use. BALF samples
were obtained by washing the lung with 0.7 + 0.5ml of PBS.
Lung wash samples were centrifuged at 9,000 × g for 10min.
The resulting supernatants were collected and stored frozen at
−40◦C until the measurement of antibodies and cytokines. HP-
β-CD or recombinant IL-33 were administered at 10%w/w or 100
ng, respectively. Alumwas administered at 100µg permouse. CT
was used after adding 1 µg of CTB to 1 ng of CT per mouse.
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Measurement of Cytokines in BALFs and
Lung Homogenate Supernatants
To evaluate the cytokines IL-33 and IL-1α in BALF, mice were
injected intranasally with PBSwith or withoutHP-β-CD, alum, or
CT. For the collection of BALF, mice were euthanatized, and their
lungs were lavaged twice with consecutive 500 µl instillations
of PBS. BALFs were collected at 0, 2, 6, 12, and 24 h after
adjuvant administration. The collected BALFs were centrifuged
at 2,500 × g for 5min at 4◦C, and the resulting supernatants
were stored at −40◦C for later use in the measurement of
cytokine levels. For the collection of lung lysates, mice were
euthanatized, and their lungs were excised and homogenized in
10ml of PBS using a gentleMACSTM Dissociator (Miltenyi Biotec,
Bergisch Gladbach, NRW, Germany). The lung homogenates
were centrifuged at 300 × g for 5min at 4◦C, and the resulting
supernatants were then centrifuged at 9,000 × g for 5min at
4◦C. The new supernatants were stored at −40◦C for later use
in the measurement of cytokine levels. The levels of IL-1α were
measured using an ELISA kit (BioLegend, San Diego, CA, USA)
in accordance with the manufacturer’s instructions. The levels of
IL-33 were measured using the following method. Briefly, 96-
well plates were coated with 2µg/ml purified anti-mouse IL-
33 antibodies (clone Poly5165; BioLegend) in PBS overnight at
4◦C. They were then washed with PBS containing 0.05% Tween-
20 (PBST) and incubated for 1 h with blocking buffer (RPMI
containing 5% FCS). After blocking, the plates were washed
and incubated with diluted BALF or recombinant IL-33 as a
standard overnight at 4◦C. They were then washed again and
incubated for 1 h with 0.5µg/ml biotin-conjugated anti-mouse
IL-33 antibody (clone Poly5165; BioLegend) in PBS with 1% BSA.
The plates were then washed again and incubated for 20min
with horseradish peroxidase (HRP)-conjugated avidin. After a
final wash, the samples were incubated with a reagent from the
TMBMicrowell Peroxidase Substrate System (KPL, Gaitherburg,
MD, USA) to initiate the color reaction, in accordance with
the manufacturer’s protocol. The reaction was stopped by the
addition of 2N H2SO4, and the optical density was measured
at a wavelength of 450 nm (OD450). Protein concentrations in
the supernatant were quantified with the Pierce BCA Protein
Assay Kit (Thermo Fisher,Waltham,MA, USA). Total RNA from
mouse lung homogenates was extracted with TRIzol LS Reagent
(Thermo Fisher, Waltham, MA, USA) and RNeasy Mini Kit
(QIAGEN, Venlo, Netherlands). RNA was reverse-transcribed
with ReverTra Ace (TOYOBO, Osaka, Japan). The expression
of genes was quantified with LightCycler R© TaqMan R© Master
and LightCycler R© 480 System (Roche, Penzberg, Germany),
according to the manufacturer’s instructions. The results are
shown as the relative expression standardized to the expression
of a gene encoding eukaryotic 18S rRNA. The specific primers
and probes used for quantitative RT-PCR were TaqMan probes
for Il33 (Cat# 4351372) and 18S rRNA (Applied Biosystems,
Waltham, MA, USA).
OVA-Specific Antibody Response
To measure the OVA-specific total IgG, IgG1, IgG2c, and IgA
in the serum and the BALF samples, flat-bottomed 96-well
microtiter plates were coated with 10µg/ml OVA in carbonate
buffer overnight at 4◦C. The plates were then washed with PBST
and incubated for 1 h with blocking buffer (PBST containing
1% BSA). After blocking, the plates were washed and incubated
with diluted serum or BALF for 2 h at room temperature.
To detect the bound antibody, the plates were washed and
incubated for 1 h with HRP-conjugated anti-mouse total IgG,
IgG1, IgG2c, or IgA antibody (Southern Biotech, Birmingham,
AL, USA). After the plates were washed, enzymatic detection
was performed with TMB soluble reagent and terminated by
the addition of 2N H2SO4. Titers of antigen-specific antibodies
were determined by log-linear interpolation of the serum dilution
value corresponding to cut-off absorbance (OD450 of 0.2).
Histological Analysis
To stain the lung tissues, the lungs were inflated with Tissue-
Tek optimal cutting temperature (OCT) compound (Sakura,
Tokyo, Japan) diluted 1:4 in PBS, subsequently embedded inOCT
compound, and frozen at−80◦C. Frozen sections (12µm) of the
isolated lung specimens were prepared, fixed, and permeabilized
with the BD Cytofix/Cytoperm Plus Fixation/Permeabilization
Kit (BD Biosciences) in accordance with the manufacturer’s
instructions. The lung specimens were incubated overnight
at 4◦C with purified anti-mouse IL-33 antibodies (clone
Poly5165; BioLegend) and anti-pro surfactant protein C (proSP-
C) antibodies (EMD Millipore; Merck KGaA, Darmstadt,
Germany). After that, we stained them with Alexa Fluor R©568
anti-goat IgG and Alexa Fluor R©647 anti-rabbit IgG (Invitrogen,
San Diego, CA, USA) for 1 h and co-stained them with DAPI
(Sigma Aldrich, St. Louis, MO, USA) for 20min. Images
were analyzed with a FluoView (FV10i) confocal microscope
(Olympus, Tokyo, Japan).
Influenza Virus Challenge
The influenza SV (1 µg) or the influenza SV plus HP-β-CD
was administered to Il33+/− or Il33−/− mice at days 0 and 14.
Two weeks after the last immunization, the mice were challenged
intranasally with 10 × LD50 of influenza virus A/PR/8/34. The
changes in body weight and the mortality of the challenged mice
were monitored for 20 days.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism6
software (GraphPad Software Inc., LaJolla, CA, USA). The data
are shown as the mean ± standard error of the mean (SEM).
Means were compared using a t-test or one-way ANOVA for
multiple groups, and p < 0.05 was considered significant.
RESULTS
Nasal Administration of HP-β-CD Raises
Levels of IL-33, but Not of IL-1α, in BALF
We previously demonstrated that the adjuvant effect of
intranasally administered HP-β-CD disappeared in Myd88−/−
mice (11). MyD88 is a downstream signaling molecule of the IL-
1 family and TLR receptors (20). As the prominent cytokines in
the lung, IL-1α is reported to be released from murine alveolar
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FIGURE 1 | IL-33 in BALF were temporary increased after intranasal administration of HP-β-CD. (A,B) IL-1α and IL-33 levels in the BALF of mice intranasally
administered a single dose of alum (100 µg/dose), cholera toxin (CT), 10% HP-β-CD, or PBS (A) or 3–20% HP-β-CD (B). Cytokine levels in the supernatants of the
BALF were measured by ELISA. Results are shown as the mean ± SEM (n = 5–6 in each group) and are representative of two experiments. **p < 0.01 compared
with mice exposed to PBS (Mann-Whitney U-test).
macrophages upon the intratracheal administration of fine
particles (21). Moreover, it is well-known that IL-33 is induced
during various immune responses in the lung (16, 22). Hence,
to investigate whether any cytokines are involved in the adjuvant
effect of HP-β-CD, we first performed a time-course analysis of
the levels of IL-1α and IL-33 in the BALF after intranasal injection
of HP-β-CD. We used alum and cholera toxin (CT) as controls
commonly used as a nasal vaccine adjuvant in animal models.
Consistent with previous results (21), the BALF levels of IL-
1α were increased in mice injected with alum (Figure 1A). In
contrast, the BALF IL-33 levels, but not the IL-1α levels, were
significantly increased in HP-β-CD-injected mice, particularly
around 6 h post-injection (Figure 1A). The observed increase in
IL-33 levels completely faded by 24 h. CT administration did not
increase the levels of either IL-1α or IL-33 in the BALF. Next, we
administered three different concentrations of HP-β-CD to mice.
As the concentrations of administered HP-β-CD increased, the
level of IL-33 in the BALF also went up (Figure 1B). Collectively,
these results clearly indicate that the nasal immunization of HP-
β-CD induced an increase in the level of IL-33 protein secreted in
the BALF.
HP-β-CD Induces Robust IL-33 Production
in Alveolar Epithelial Type 2 (AT2) Cells
It is of note that intranasal administration of mice with HP-β-CD,
but not with alum or CT, induced IL-33 secretion in the BALF
in 6 h, without inducing IL-1α, while all of the adjuvants were
shown to release same amount of dsDNA into BALF 6 h after
administration (11). As IL-1α and IL-33 are nuclear cytokines
induced in different cell types (16, 21), we thus hypothesized that
the cell type(s) that respond to each adjuvant may be different.
In order to determine which cells in the lung produced the IL-33
observed in the BALF after an intranasal injection of HP-β-CD,
we performed immunohistochemistry to stain IL-33 in the lung
tissue at the different time points. Higher level of IL-33 were
detected in the lung tissues at 24 h after HP-β-CD administration
than at 6 h (Figure 2A) although the peak of IL-33 level in
BALF was at 6 h (Figure 1A). Interestingly, CT also increased
the level of IL-33 at 24 h (Figure 2A). When we examined the
co-localization of IL-33 and alveolar epithelial type 2 (AT2)
cells, known to be the major cellular source of IL-33 in murine
lungs (16, 18), IL-33 induced by HP-β-CD was restricted to pro-
surfactant protein C (pro-SPC)-positive AT2 cells (Figure 2B),
suggesting that IL-33 released by HP-β-CD may be released from
the AT2 cells.
We previously reported that TANK-binding kinase 1 (TBK1),
a cytosolic kinase that is essential for the activation of
nucleic acid-dependent downstream signaling, is involved in
the induction of immune responses resulting from intranasal
HP-β-CD immunization (10). Moreover, it is reported that
IL-33 induction is dependent on TBK1-dependent signaling
pathway (22). However, a similar level of IL-33 expression
was also observed in lung tissues from intranasally HP-β-CD-
administered TBK1-deficient mice (Figure S1). This finding
suggests that TBK1 signaling is not involved in IL-33 induction
after intranasal HP-β-CD administration. Taken together, these
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FIGURE 2 | HP-β-CD induced expression of IL-33 from AT2 in the lung. Mice were intranasally administered a single dose of PBS, HP-β-CD, or CT. (A,B)
Representative images of lung sections collected from these mice at 6 (A) or 24 h (A,B) after intranasal administration and subjected to immunohistochemistry for
IL-33 (red) (A,B) and pro-SPC (green) and co-stained with DAPI (blue) (B). White scale bar = 50µm. (C,D) IL-33 protein levels in the supernatants of lung
homogenates from 24h (C) and mRNA levels in lung tissues from 6h (D) after intranasal administration with alum, cholera toxin, HP-β-CD, or PBS as determined by
ELISA and q-PCR, respectively. Results are shown as the mean ± SEM (n = 5–6 in each group) and are representative of two experiments. *p < 0.01 compared with
mice exposed to PBS (Mann-Whitney U-test).
results demonstrate that HP-β-CD induced IL-33 production
from AT2 cells in TBK-independent mechanism.
The different pattern of IL-33 level in BALF samples and
lung sections attempted us to identify more precise mechanism
of HP-β-CD to induce the production of IL-33. Recent results
have shown that IL-33 functions as an alarmin following
the release into the extracellular space by cellular damage or
mechanical injury (23). Thus, IL-33 detected in the BALF after
the intranasal administration of HP-β-CD is assumed to reflect
only the active form of which was released from the cells. To
analyze whether HP-β-CD enhances the production of IL-33
as well as the release of it, we measured the protein level of
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FIGURE 3 | Antibody responses in serum and BALF were hardly increased in
HP-β-CD-adjuvanted IL-33 and ST2 knockout mice. (A) Time schedules for
the vaccination and sampling of blood and BALF. Each dose contained 10µg
(Continued)
FIGURE 3 | of OVA plus 10% HP-β-CD. (B,C) Il33+/−, Il33−/− (B), St2+/−, or
St2−/− (C) mice were immunized with OVA ± HP-β-CD according to the
schedule illustrated in (A). Serum and BALF were collected 14 days after the
last immunization, and OVA-specific total IgG, IgG1, IgG2c, and IgA levels
were measured via ELISAs. The graphs show titers (mean ± SEM, n = 5).
Data are representative of three independent experiments. *p < 0.01
(Mann-Whitney U-test).
IL-33 in the supernatant of homogenized lung tissues from
the mice intranasally injected with HP-β-CD. In consistent
with immunohistochemistry data, the level of IL-33 in the
homogenized lung tissue were increased by the intranasal
administration of HP-β-CD (Figure 2C). Furthermore, a rapid
increase of IL-33 mRNA was also observed after the intranasal
administration of HP-β-CD. It is worth to mention that mRNA
and protein levels of IL-33 in homogenized lung tissues were also
elevated following the intranasal administration of alum or CT
while they did not increase IL-33 in BALF (Figures 1A, 2C,D).
Taken together, these results suggested that HP-β-CD induces not
only the temporal release of IL-33, but also the production in
mainly AT2 cells.
The Adjuvant Effect of HP-β-CD Nasal
Administration Disappears in Il33−/– Mice
Next, we investigated whether IL-33 plays an important role
in HP-β-CD adjuvanticity using innate immune deficient mice.
Interestingly, the adjuvanticity of HP-β-CD was distinct from
PAMP-driven immune-enhancing effects; OVA-specific IgG
titers in Tlr4−/−, Tlr7−/−, and Tlr9−/− mice after HP-β-CD-
OVA vaccination was equivalent to that of wild type (WT) mice
(Figure S2A). Therefore, to verify whether IL-33 contributed
to the adjuvanticity of HP-β-CD, WT and Il33−/− mice were
immunized intranasally twice with OVA plus HP-β-CD, and
the resulting OVA-specific antibody titers in the serum and
BALFwere quantified on day 28 post-immunization (Figure 3A).
In sharp contrast to WT mice, the adjuvant effect of HP-β-
CD completely disappeared in the Il33−/− mice, and there
was no difference in the OVA-specific antibody titers following
the administration of OVA plus HP-β-CD as compared with
the administration of OVA alone in these mice (Figure 3B).
Additionally, the adjuvanticity was also observed in mice that
were immunized with OVA plus recombinant IL-33 instead of
HP-β-CD by intranasal administration (Figure S3). These results
are consistent with the observation that IL-1 family cytokines,
including IL-33, leads to display a mucosal adjuvant effect
following their nasal administration (24).
Airway epithelial cells also produce innate cytokines, such as
IL-1α, IL-25, and thymic stromal lymphopoietin (TSLP) as well
as promote Th2-type immunity. Using a similar experimental
set-up, we evaluated the involvement of these cytokines in HP-β-
CD adjuvanticity. When HP-β-CD was administered to IL-1α- or
TSLP-deficient mice, thesemice, likeWTmice, exhibited a robust
production of anti-OVA total IgG antibody, although the Il1α−/−
mice had slightly lower levels of it (Figure S2B). Moreover,
mice lacking IL-1R1, which is the specific receptor for IL-1α
and IL-1β, had levels of anti-OVA total IgG antibody that were
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FIGURE 4 | IL-33 signaling affected the adjuvanticity only in intranasal administration of HP-βCD. (A–C) Il33+/− or Il33−/− mice were immunized intranasally (A–C) or
subcutaneously (B,C) with 10 µg of OVA plus 10% HP-β-CD, CT, or 100 µg of alum on days 0 and 14. The anti-OVA total IgG, IgG1, and IgG2c antibody titers in
serum (A,B) and anti-OVA total IgG, IgG1, and IgA antibody titers in BALF (C) were measured via ELISA 14 days after the last immunization. SC, subcutaneous; IN,
intranasal. Results are representative of three independent experiments and are shown as the mean ± SEM of 5–6 mice in all groups. *p < 0.05 (Mann-Whitney
U-test).
comparable with those of WT animals (Figure S2B), whereas
mice lacking ST2 (IL-1RL1), the receptor for IL-33, were unable
to produce detectable levels of anti-OVA total IgG antibody
(Figure 3C). These findings suggest that IL-33/ST2 signaling is
more dominant in the adjuvant effect of nasally administered
HP-β-CD than other innate cytokine-mediated signaling.
ST2 is expressed on Th2 cells, innate lymphoid type 2 (ILC2)
cells, eosinophils, basophils, and mast cells, among others, and
they induce the immune responses by producing Th2 cytokines.
To investigate the involvement of the major Th2 cytokine IL-13
in the adjuvant effect of HP-β-CD, we nasally administered HP-
β-CD to Il13−/− mice. The serum anti-OVA antibody titers of
HP-β-CD-adjuvanted IL-13-deficient mice were not significantly
different from those of similarly treated WT mice, but the
anti-OVA IgA antibody titer in the BALF of these mice was
significantly lower (Figure S2C). Based on these data together
with the data showing that IL-33 has an important role in our
model, we concluded that the immune responses that occur
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FIGURE 5 | The induction of IL-33 by intranasally HP-β-CD protected against influenza infection. (A) Experimental timeline. (B) Il33+/− or Il33−/− mice were vaccinated
with the influenza split vaccine (1 µg) in combination with or without HP-β-CD on days 0 and 14. Two weeks after the last immunization, the mice were challenged
with 10 × LD50 of influenza virus A/PR/8/34. Changes in mortality (left) and body weight (right) were monitored for 20 days. *p < 0.05 [Log-rank (Mantel-Cox) test].
after HP-β-CD immunization might be induced by signals from
IL-33/ST2 signaling through MyD88.
Intranasal Administration of HP-β-CD Has
a Unique Mode of Action of Adjuvanticity
To further characterize the role of IL-33 in adjuvant effects
in general, we investigated the requirement for this cytokine
following the use of other adjuvants and administration routes.
First, we evaluated the antibody responses in alum- or CT-
adjuvanted IL-33-deficient mice. Unlike in HP-β-CD-treated
Il33−/− mice, the antibody responses in the serum and BALF
were not decreased in alum- or CT-adjuvanted Il33−/− mice
compared with similarly treated WT mice (Figure 4A). Second,
to explore the possibility that IL-33 might also be involved in
the effect of subcutaneous injection with HP-β-CD, we compared
the involvement of IL-33 in the antibody responses induced
by subcutaneous and intranasal HP-β-CD administration. The
induced OVA-specific antibody responses in the serum fromWT
mice were equivalent between subcutaneously and intranasally
HP-β-CD-injected mice. However, in the case of IL-33−/−
mice injected with HP-β-CD, the production of OVA-specific
antibody responses was abolished in the intranasally HP-β-
CD-administered mice, whereas the subcutaneously HP-β-CD-
immunized mice had robust antibody responses (Figure 4B). In
addition, the disappearance of OVA-specific antibody production
in these mice occurred not only in the serum (IgG) but also in
the BALF (IgA) (Figure 4C). Thus, IL-33 is not required for the
adjuvanticity of subcutaneously administered HP-β-CD. These
findings were consistent with previous reports that alum induces
a completely different response depending on its administration
route (21, 25–27). Taken together, these results indicate that
stimulation of the IL-33-dependent pathway is unique to the
adjuvanticity of intranasally administered HP-β-CD.
HP-β-CD-Induced IL-33 Enhances
Protective Immunity Against PR8 Influenza
Virus
Intranasal vaccination with HP-β-CD as an adjuvant has been
previously shown to enhance protection against lethal influenza
infection (11). To confirm the protective role of IL-33 during
influenza infection, we immunized Il33+/− or Il33 −/− mice with
the influenza split vaccine plus HP-β-CD following PR8 infection
(Figures 5A,B). In agreement with the previous report, Il33+/−
mice were protected against PR8 virus infection following
vaccination that was adjuvanted with HP-β-CD. In contrast, the
protection provided by this vaccine and adjuvant combination
was lost in Il33−/− mice. Additionally, compared with WT
mice, unvaccinated Il33−/− mice showed the same susceptibility
to infection. Furthermore, we investigated that HP-β-CD was
also able to increase antibody titers against influenza vaccine as
well as OVA. Of note, the immune response induced by HP-
β-CD was abolished in IL-33 KO mice (Figure S4). These data
support the novel finding that the IL-33 induced by the intranasal
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administration of HP-β-CD can contribute to protection against
influenza virus infection.
DISCUSSION
The purpose of a vaccine is to allow immunocompetent cells
to recognize the vaccine antigen(s) when the host is exposed to
the corresponding pathogen, so they can induce an appropriate
immune reaction. Vaccine development has shifted focus from
the classical live-attenuated and inactivated vaccines to subunit
vaccines, which consist of purified proteins, emphasize safety,
and may also have applications in non-infectious diseases, such
as cancer. However, many antigens do not elicit strong immune
responses on their own. Consequently, current vaccines often
contain adjuvants that can activate the innate immune system to
promote the recognition and presentation of antigens by antigen-
presenting cells (APCs) and subsequent cell-mediated and
humoral immune responses (1). Ligands that themselves activate
innate immunity have been studied as vaccine adjuvants, as
have damage-associated molecular patterns (DAMPs)-inducing
molecules, which cause cell damage and DAMPs release,
thus resulting in an enhanced innate immune response (4).
However, the mechanisms of action of these adjuvants are
poorly understood. Alum is classified as a DAMPs inducer
(28, 29), but the mode of action of even this widely used
adjuvant has not yet been fully described. Because vaccines are
administered to healthy people in most cases, the requirement
for safety is extremely high, and there is a need to clarify the
mechanism of action of adjuvants for their practical use. In this
work, we found that HP-β-CD in the respiratory tract mediates
immune enhancement via IL-33, in a manner that is distinct
from conventional PAMP signaling-based adjuvants. This is the
first adjuvant reported to induce humoral immune responses
via IL-33.
In our experiment, we performed two types of IL-33
measurement. One is the level of IL-33 in the BALF, which
allowed the observation of IL-33 release in the respiratory tract,
and the other is the level of IL-33 in lung tissues, which allowed
the observation of IL-33 gene expression in the lungs. As shown
Figure 1A, the IL-33 level in the BALF of HP-β-CD-treated mice
increased and peaked at 6 h after intranasal administration. In
contrast, strong IL-33 protein expression was observed in the
lung tissues at 24 h after HP-β-CD intranasal administration, and,
furthermore, the IL-33 mRNA expression level also increased
and peaked at 6 h after HP-β-CD intranasal injection. These
results indicate that HP-β-CD can induce both the release of IL-
33 protein and the additional gene expression of IL-33 in the
lungs. Although alum and CT were also observed to increase the
expression of IL-33 at 24 h after intranasal injection, we found
that these adjuvants could induce the gene expression of IL-33
in the lungs but were unable to elicit the extracellular release of
IL-33. Other studies have concluded that the release of IL-33 in
the BALF corresponds with a change to a more active state under
inflammatory conditions (30). The other studies have concluded
that exogenous IL-33, but not endogenous IL-33, is involved in
viral infection (31). These results suggest that the release of IL-
33, rather than IL-33 gene expression, might be essential for the
adjuvant activity of intranasally administered HP-β-CD.
IL-33 is constitutively expressed in various cells, but the
primary source of this cytokine in the lung is airway epithelial
cells (16, 32). We observed that the IL-33 expression detected by
tissue staining was consistent with pro-SPC-expressing AT2 cells;
however, we could not resolve what type of cell death or stress was
responsible for the effect of HP-β-CD intranasal administration
or how IL-33 is released into the extracellular space. IL-33 is
normally evoked by necrotic cell death caused by mechanical or
oxidative stress. Conversely, in some situations, such as specific
mechanical or oxidative stresses or cell activation through
ATP signaling, IL-33 is secreted in the absence of cell death
(33–36), whereas upon the commencement of programmed
cell death, IL-33 signaling is abrogated (37). Previous studies
have reported that DNA release due to cell death indirectly
stimulated immune responses through IL-33 (38). It was found
that cyclodextrins, particularly β-CDs, extract cholesterol and
phospholipids from biological membranes by tapping them into
their hydrophobic cores, resulting in the induction of cell death
via several pathways (39–42). Thus, further experiments are
necessary to determine the mechanisms of IL-33 release after
HP-β-CD intranasal administration.
The adjuvant effect of aluminum salts has been extensively
studied for many years, and it is thought that upon intratracheal
instillation, aluminum salts cause the cell death of alveolar
macrophages, which then release IL-1α in the lung, resulting
in the induction of type-2 immune responses (21). In our
experiments, the induction of IL-1α was also observed after alum
intranasal administration (Figure 1A). In contrast, we found
that IL-33/ST2 signaling was involved in the adjuvanticity of
intranasally administered HP-β-CD. As shown in Figure 1A,
HP-β-CD intranasal injection temporarily increased the level
of IL-33 but not the level of IL-1α. In the murine lungs, the
primary source of IL-33 is alveolar epithelial cells. Thus, we
propose that intranasally administered HP-β-CD induces cell
damage or death in alveolar epithelial cells, which then release
IL-33 into the lung tissues. Moreover, although both alum
and HP-β-CD are categorized as DAMPs-inducing adjuvants,
it appears that they have distinct mechanisms of adjuvanticity
which may be caused from the difference of the target cells to
induce DAMPs release. Additionally, we found that the adjuvant
effect of subcutaneously administered HP-β-CD, unlike that
of intranasally administered HP-β-CD, was not related to IL-
33. This difference could be explained by a lower level of IL-
33 expression in the skin tissue compared with lung tissues
(43, 44). Our results indicate that the IL-33-mediated immune
pathway is important for the intranasal administration, but
not subcutaneous administration, of HP-β-CD. In support of
this, previous studies have demonstrated that mechanisms for
protease-dependent sensitization differ between subcutaneous
and intranasal administration routes (45). Collectively, these
findings indicate that the types of DAMP induced by an adjuvant
are distinct between administration routes, resulting in the
induction of tissue-specific immune responses.
In this study, we could not identify which type of the cells
modulates the immune-enhancing effects by recognizing high
levels of IL-33 after intranasal administration of HP-β-CD.
Notably, the adjuvant effect induced by HP-β-CD intranasal
administration was absent in St2−/− mice. ST2 is a receptor of
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IL-33 that is expressed in various cells, such as Th2 cells, ILC2
cells, mast cells, and regulatory T cells (46). We focused on IL-
13, which is produced excessively by ILC2 cells and is critical
for T-cell differentiation into Th2 cells. However, in experiments
in which HP-β-CD was administered intranasally to Il13−/−
mice, the local immune response, but not the systemic immune
response, was partially attenuated. Furthermore, mast cells may
play an essential role in the induction of the antigen-specific
mucosal immune responses induced by IL-33 (24, 47). It is the
future task for us to identify the involvement of these cells in the
immune responses by HP-β-CD inducible IL-33.
We found that the protective ability of an influenza vaccine
administered with HP-β-CD against a lethal dose of PR8
influenza virus infection was decreased in Il33−/− mice. We
also confirmed that the baseline protective immunity is not
different between Il33+/− and Il33−/− mice (data not shown).
The antibody titer against HA is also increased by HP-β-CD,
and the adjuvant effect of HP-β-CD is abolished in Il33−/−
mice as well as OVA (Figure S4). These data indicate that IL-
33 induced by the intranasal administration of an HP-β-CD-
adjuvanted vaccine is also involved in the prophylactic efficacy
against influenza virus infection. Previous studies have reported
that intratracheal administration of exogenous IL-33 is effective
in protecting against influenza infection (31). Although this
report concluded that IL-33 is involved in type1 immunity, in
our model, IL-33 was involved in antibody production. As it has
been reported that intranasal administration of HA antigen and
IL-33 in BALB/cmice increased serum IgG1 as well as IgG2a (24),
and the influenza infection after intranasal administration of IL-
33 in mice produced IL-12p40 in BALF and increased IFN-γ
production in the lung (31), the vaccine adjuvant effect of HP-
β-CD in flu vaccine may induce type 1 immunity via IL-33. In
fact, we have shown previously that IgG2c subtype enhanced by
HP-β-CD adjuvanted influenza vaccine in addition to IgG1 (12).
Although we have not observed strong type-1 immune responses
characterized by the induction of CD4+ Th1 cells and CD8+
T cells by HP-β-CD adjuvanted influenza vaccine, we are keen
to investigate the mechanism of the adjuvant effect of HP-β-CD
on influenza antigen in near future, as we conducted a human
clinical trial, in which HP-β-CD was used as an adjuvant for
seasonal 4-valent influenza vaccine (UMIN000028530). Future
work should investigate the in vivo consequences of an increased
antibody titer that is completely dependent on IL-33 as caused by
intranasally administered HP-β-CD.
The most intriguing part of this study is the biological
significance of the immune system controlled by a single factor of
IL-33, such as that induced by HP-β-CD. It is well-known that IL-
33 is necessary for parasite protection (48, 49), but this induction
of antibody production is completely controlled only by IL-33,
while IL-1a, an important inflammatory cytokine in the lung
(20, 21), is not involved. In general, IFN and Th1 response play
an important role in virus infection, but some viruses circumvent
such mechanisms by various means (50). The immune defense
mechanism controlled by IL-33 may be a back-up system with
an alarm for cell damage by such viruses. A recent studies have
reported that IL-33 is involved in the protection of hepatitis
viruses and HIV (51, 52). This study seems to be a valuable model
for observing antibody production via IL-33 alone.
In conclusion, we found that the intranasal administration
of HP-β-CD induces IL-33 release from AT2 cells along with
humoral immune responses. These effects were not observed
following the subcutaneous administration of HP-β-CD or the
intranasal administration of other adjuvants. An improved
understanding of the molecular mechanisms of adjuvants will
guide research efforts to develop new adjuvants.
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